Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia (CLL)
Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-3412
Full Text
Open PDFAbstract
Available in full text
Date
April 2, 2019
Authors
Publisher
American Association for Cancer Research (AACR)